secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0001370053-24-000067
Event type: other_material
Sentiment:  negative
Materiality: 0.78
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio Phase 2B trial of ANB032 fails endpoints in atopic dermatitis; cash ~$415M
--------------------------------------------------------------------------------

- ANB032 did not meet primary endpoint EASI-75 or any secondary endpoints at Week 14 in 201-patient ARISE-AD trial.
- Higher placebo rates than historical norms, particularly in U.S., contributed to failure; drug well tolerated with no safety signals.
- Cash, equivalents and investments expected to be ~$415M at Dec 31, 2024, funding operations through year-end 2027.
- One serious adverse event (worsening AD) across active arms; no dose relationship or imbalance in adverse events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005324000067/0001370053-24-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005324000067/anab-20241211.htm
  HTML page:      https://secwatch.observer/filing/0001370053-24-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer